VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
VYNE Therapeutics Inc. (Nasdaq: VYNE) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before market hours.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before market hours. A conference call will be held at 8:30 a.m. ET to discuss the results and provide updates. VYNE specializes in developing innovative dermatological therapies, having received FDA approvals for AMZEEQ® and ZILXI™, both minocycline topical foams. The company emphasizes its commitment to improving patient lives through proprietary technologies.
Positive
- FDA approval of AMZEEQ® and ZILXI® enhances product portfolio.
- Upcoming conference call may provide positive updates and financial guidance.
Negative
- None.
Details
News Market Reaction – VYNE
The recorded move for VYNE in the trading session of this news was -9.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
| Conference Call | |||
| Thursday, November 5th @ 8:30am Eastern Time | |||
| Toll Free: | 800-289-0438 | ||
| International: | 323-794-2423 | ||
| Conference ID: | 9576782 | ||
| Webcast: | http://public.viavid.com/index.php?id=142196 | ||
A replay of the call will be archived on the Company’s website at https://vynetherapeutics.com promptly after the conference call.
About VYNE Therapeutics Inc.
VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam,
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Media Relations:
Bridgette Potratz
Zeno Group
312-358-2950
bridgette.potratz@zenogroup.com
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com
Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.